Loading
Children with standard-risk hepatoblastoma were cured just as often with cisplatin alone as with cisplatin plus doxorubicin, and had far fewer severe side effects, so doxorubicin can be left out.
International randomised trial of the SIOPEL group: 255 children with standard-risk hepatoblastoma were randomised to pre- and post-operative cisplatin alone (n 126) or cisplatin plus doxorubicin (n 129) with delayed resection.
Complete resection was achieved in 95 and 93 percent; three-year event-free survival was 83 and 85 percent and overall survival 95 and 93 percent (median follow-up 46 months). Acute grade 3 or 4 adverse events occurred in 20.6 percent with cisplatin alone against 74.4 percent with the combination.
Cisplatin monotherapy with delayed surgery is the standard for standard-risk hepatoblastoma; later SIOPEL-6 added sodium thiosulfate to protect hearing.
Shares Hepatoblastoma, Doxorubicin, Cisplatin.
Shares Hepatoblastoma, Doxorubicin, Cisplatin.
Shares Hepatoblastoma, Doxorubicin, Cisplatin.
Shares Hepatoblastoma, Cisplatin.
Shares Hepatoblastoma, Doxorubicin, Cisplatin.
Shares Hepatoblastoma, Doxorubicin.